Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Telomir Pharmaceuticals, Inc. (TELO) had Stock-Based Compensation of $0.90M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-0.71M |
|
-- |
|
-- |
|
$0.75M |
|
$-0.75M |
|
$0.04M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.71M |
|
$-0.75M |
|
$-0.75M |
|
68.78M |
|
68.78M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$4.64M |
|
-- |
|
-- |
|
$4.64M |
|
$0.24M |
|
-- |
|
-- |
|
$0.24M |
|
$4.40M |
|
$4.40M |
|
$4.40M |
|
68.78M |
|
| Cash Flow Statement Financials | |
$-3.37M |
|
-- |
|
$0.60M |
|
$7.29M |
|
$4.52M |
|
$-2.77M |
|
|
Stock-Based Compensation |
$0.90M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.60 |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.37M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.01% |
|
-16.01% |
|
-15.19% |
|
-16.01% |
|
$0.06 |
|
$-0.05 |
|
$-0.05 |
|